Fig. 1 · Structure
Documents & Downloads
Topiramate lithium
Antiepileptic Agent
Topiramate lithium is a broad-spectrum antiepileptic agent targeting multiple pathways. As a GluR5 receptor antagonist, it enhances GABAergic activity while inhibiting kainate/AMPA receptors and modulating voltage-sensitive sodium and calcium channels. Its mechanism also includes increased potassium conductance and inhibition of carbonic anhydrase. These combined effects make Topiramate lithium valuable for research into epilepsy and other neurological disorders.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 488127-53-3 |
| Applications | Antiepileptic Agent |
| Formula | C12H21LiNO8S |
| Molecular Weight | 346.30 |
| Synonyms | McN 4853 lithium; RWJ 17021 lithium |
| SMILES | NS(OC[C@]1(OC(C)(C)O2)[C@@H]2[C@H](OC(C)(C)O3)[C@H]3CO1)(=O)=O.[Li] |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.